Comparative Pharmacology
Head-to-head clinical analysis: MACUGEN versus ZALTRAP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MACUGEN versus ZALTRAP.
MACUGEN vs ZALTRAP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pegaptanib is a pegylated modified oligonucleotide that binds to and inhibits vascular endothelial growth factor (VEGF-165), reducing angiogenesis and vascular permeability.
Vascular endothelial growth factor (VEGF) trap; binds to VEGF-A, VEGF-B, and PlGF, inhibiting angiogenesis.
Intravitreal injection of 0.3 mg (0.09 mL) once every 6 weeks.
4 mg/kg intravenously over 1 hour every 2 weeks
None Documented
None Documented
The terminal elimination half-life in plasma is approximately 10 days following intravitreal administration, consistent with slow clearance from the vitreous cavity and systemic absorption.
17-18 days (terminal half-life) with clinical context supporting a dosing interval of every 2 weeks; steady-state achieved by approximately 16 weeks.
Pegaptanib is eliminated primarily via renal excretion, with the parent compound and metabolites excreted in urine accounting for >90% of the administered dose. Biliary/fecal elimination is negligible (<5%).
Primarily via the reticuloendothelial system and proteolytic catabolism; no significant renal or biliary excretion. Renal elimination accounts for <5% as intact drug.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor